Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Malvern Panalytical’s Materials Research ...

Moreover, oligometastatic ccRCC poses a unique challenge for MRD assays because tumors tend to be heterogeneous, slow growing, low shedding, and generally limited in trackable mutations 1.

Minimal residual disease (MRD) is a key focus in multiple myeloma treatment decision-making, offering prognostic insights and potential treatment guidance. Clinicians use MRD variably, with some ...

This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO ...